- Home
- MGN vs MRSN Comparison
MGN vs MRSN Comparison
Compare MGN & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGN
- MRSN
- Stock Information
- Founded
- MGN 2020
- MRSN 2001
- Country
- MGN Malaysia
- MRSN United States
- Employees
- MGN N/A
- MRSN N/A
- Industry
- MGN
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MGN
- MRSN Health Care
- Exchange
- MGN Nasdaq
- MRSN Nasdaq
- Market Cap
- MGN 43.0M
- MRSN 47.1M
- IPO Year
- MGN 2025
- MRSN 2017
- Fundamental
- Price
- MGN $1.50
- MRSN $27.87
- Analyst Decision
- MGN
- MRSN Buy
- Analyst Count
- MGN 0
- MRSN 5
- Target Price
- MGN N/A
- MRSN $30.38
- AVG Volume (30 Days)
- MGN 637.0K
- MRSN 211.4K
- Earning Date
- MGN 11-28-2025
- MRSN 11-14-2025
- Dividend Yield
- MGN N/A
- MRSN N/A
- EPS Growth
- MGN N/A
- MRSN N/A
- EPS
- MGN 0.07
- MRSN N/A
- Revenue
- MGN $13,484,571.00
- MRSN $33,180,000.00
- Revenue This Year
- MGN N/A
- MRSN N/A
- Revenue Next Year
- MGN N/A
- MRSN N/A
- P/E Ratio
- MGN $21.59
- MRSN N/A
- Revenue Growth
- MGN N/A
- MRSN N/A
- 52 Week Low
- MGN $1.30
- MRSN $5.21
- 52 Week High
- MGN $8.63
- MRSN $70.73
- Technical
- Relative Strength Index (RSI)
- MGN N/A
- MRSN 89.87
- Support Level
- MGN N/A
- MRSN $7.59
- Resistance Level
- MGN N/A
- MRSN $28.07
- Average True Range (ATR)
- MGN 0.00
- MRSN 0.69
- MACD
- MGN 0.00
- MRSN 1.80
- Stochastic Oscillator
- MGN 0.00
- MRSN 99.51
About MGN Megan Holdings Limited Ordinary Shares
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.